Weaver Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Weaver Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-387	Closed	-$218K	–	201
2025 Q3	$218K	Sell	387 -770	-67%	-$435K	0.05%	161
2025 Q2	$607K	Sell	1,157 -178	-13%	-$99.3K	0.15%	123
2025 Q1	$847K	Sell	1,335 -46	-3%	-$31.6K	0.22%	102
2024 Q4	$984K	Sell	1,381 -526	-28%	-$441K	0.27%	96
2024 Q3	$2M	Hold	1,907	–	–	0.6%	50
2024 Q2	$2M	Buy	1,907 +31	+2%	+$30.1K	0.64%	48
2024 Q1	$1.81M	Buy	1,876 +171	+10%	+$163K	0.62%	49
2023 Q4	$1.5M	Buy	+1,705	New	+$1.4M	0.59%	52

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Weaver Capital Management's REGN Position: Q4 2025 in Review

Weaver Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 387 shares — an estimated $218K sold.

Weaver Capital Management first reported a position in REGN in Q4 2023 and held it in 8 quarters. The position peaked at $2M in Q3 2024. 1,388 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

Weaver Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Weaver Capital Management sold 387 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $218K.
Weaver Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2023 and held it in 8 quarters.
Weaver Capital Management's Regeneron Pharmaceuticals position peaked at $2M in Q3 2024.
1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Weaver Capital Management's 13F filing for Q4 2025, filed 22 Jan 2026.